New uses for new and old quinolones and the challenge of resistance

Clinical Infectious Diseases

Volumn 30, Issue 2, 2000, Pages 243-254

  Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CISAPRIDE; GREPAFLOXACIN; LEVOFLOXACIN; MORPHINE; QUINOLONE DERIVATIVE; SPARFLOXACIN; SUCRALFATE; THEOPHYLLINE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; PIPERAZINES; RESPIRATORY TRACT INFECTIONS; SENSITIVITY AND SPECIFICITY; SEXUALLY TRANSMITTED DISEASES; URINARY TRACT INFECTIONS;

EID: 0034095261     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313677     Document Type: Review

References (109)

1. 1. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324:384-94.
2. 2. Hooper DC. Clinical applications of quinolones. Biochim Biophys Acta Gene Struct Expression 1998; 1400:45-61.
3. 3. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47:677-700.
4. 4. Anonymous. Grepafloxacin - a new fluoroquinolone. Med Lett Drugs Thcr 1998; 40:17-8.
5. 5. Anonymous. Trovafloxacin. Med Lett Drugs Ther 1998; 40:30-1.
6. 6. Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53:817-24.
7. 7. Anonymous. Sparfloxacin and levofloxacin. Med Lett Drugs Ther 1997; 39: 41-3.
8. 8. Haria M, Lamb HM. Trovafloxacin. Drugs 1997; 54:435-45.
9. 9. Felmingham D, Robhins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997; 39:43-9.
10. 10. Visser MR, Rozenberg-Arska M, Beumer H, Hoepelman IM, Verhoef J. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother 1991; 35: 858-68
11. 11. Rolston KV, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother 1990; 34:2263-6.
12. 12. Marco F, Jones RN, Hoban DJ, Pignatari AC, Yamane N, Frei R. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother 1994; 33:647-54.
13. 13. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y, Lab IG. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996 1997 respiratory season. Diagn Microbiol Infect Dis 1997; 29:249-57.
14. 14. Loo VG, Lavellee J, McAlear D, Robson HG. The in-vitro susceptibilities of 326 Streptococcus pneumoniae isolates to nine antimicrobial agents including penicillin and newer quinolones. J Antimicrob Chemother 1994; 33:641-5.
15. 15. Wise R, Andrews JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997; 40:27-30.
16. 16. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:478-80.
17. 17. Von Eiff C, Peters G. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci. J Antimicrob Chemother 1996; 38: 259-63.
18. 18. Baquero F, Canton R. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 1996; 37:1-18.
19. 19. Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. J Antimicrob Chemother 1996; 37:1011-6.
20. 20. Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988; 32: 1336-40.
21. 21. Simor AE, Fuller SA, Low DE. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob Agents Chemother 1990; 34:2283-6.
22. 22. Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first-and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40:1610-6.
23. 23. Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991; 35:1933-6.
24. 24. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994; 38:2471-6.
25. 25. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41:2256-60.
26. 26. Teng RL, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother 1997; 39:87-92.
27. 27. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother 1996; 37:27-39.
28. 28. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin a new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
29. 29. Efthymiopoulos C. Pharmacokinetics of grepafloxacin. J Antimicrob Chemother 1997; 40:35-43.
30. 30. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug alatrofloxacin. J Antimicrob Chemother 1997; 39:75-80.
31. 31. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993; 25:358-69.
32. 32. Melnik G, Schwesinger WH, Teng R, Dogolo LC, Vincent J. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. Eur J Clin Microbiol Infect Dis 1998; 17:424-6.
33. 33. Efthymiopoulos C, Bramer SL, Maroli A, Gambertoglio JG. Effect of renal impairment on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997; 33:32-8.
34. 34. Fillastre JP, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother 1994; 38:733-7.
35. 35. Efthymiopoulos C, Bramer SL, Maroli A, et al. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction. Clin Pharmacokinet 1997; 33:25-31.
36. 36. Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997; 41:1668-72.
37. 37. Teng RL, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997; 39:93-7.
38. 38. Vincent J, Hunt T, Teng RL, Robarge L, Willavize SA, Friedman HL. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects. Am J Surg 1998; 176:32S-8S.
39. 39. Efthymiopoulos C, Bramer SL, Maroli A, Blum B. Theophylline and warfarin interaction studies with grepafloxacin. Clin Pharmacokinet 1997; 33:39-46.
40. 40. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352-64.
41. 41. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998; 42:114-20.
42. 42. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996; 37:145-60.
43. 43. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996; 37:161-7.
44. 44. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. Antimicrob Agents Chemother 1998; 42:2262-6.
45. 45. Naber KG, Di Silverio F, Geddes A, Guibert J. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. J Antimicrob Chemother 1996; 37:135-44.
46. 46. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998; 52:51-5.
47. 47. Moi H, Morel P, Gianotti B, Barlow D, Phillips I, Jean C. Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men. J Antimicrob Chemother 1996; 37(Suppl A):115-22.
48. 48. Hook EW III, McCormack WM, Martin D, et al. Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1997; 41:1843-5.
49. 49. Jones RB, Schwebke J, Thorpe EM Jr, et al. Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Am J Med 1998; 104:28-32.
50. 50. Bogaerts J, Tello WM, Akingeneye J, Mukantabana V, Van Dyck E, Piot P. Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda. Genitourin Med 1993; 69:196-200.
51. 51. Hooton TM, Batteiger BE, Judson FN, Spruance SL, Stamm WE. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36:1144-6.
52. 52. Phillips I, Dimian C, Barlow D, et al. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1996; 37:123-34.
53. 53. McCormack WM, Martin DH, Hook EW III, Jones RB. Daily oral grepafloxacin vs. twice daily oral doxycyline in the treatment of Chlamydia trachomatis endocervical infection. Infect Dis Obstet Gynecol 1998; 6: 109-15.
54. 54. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous oral treatment with ciprofloxacin plus metronidazole to imipenem cilastatin for intra-abdominal infections. Ann Surg 1996; 223:303-15.
55. 55. Donahue PE, Smith DL, Yellin AE, et al. Trovafloxacin in the treatment of intra-abdominal infections: results of a double blind, multicenter comparison with imipenem/cilastatin. Am J Surg 1998; 176:53S-61S.
56. 56. Roy S, Koltun W, Chatwani A, et al. Treatment of acute gynecologic infections with trovafloxacin. Am J Surg 1998; 176:67S-73S.
57. 57. Nichols RL, Smith JW, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997; 90:1193-200.
58. 58. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respiratory Care 1997; 42:206-13.
59. 59. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 1998; 7:101-9.
60. 60. Allegra L, Konietzko N, Leophonte P, et al. Safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother 1996; 37:93-104.
61. 61. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin vs. ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis - a multicenter, double-blind, randomized, comparative study. Chest 1998; 114: 120-30.
62. 62. Langan CE, Cranfield R, Breisch S, Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40: 63-72.
63. 63. O'Doherty B, Daniel R, Trovafloxacin Bronchitis Study Group. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Eur J Clin Microbiol Infect Dis 1998; 17:441-6.
64. 64. Leophonte P, Baldwin RJ, Pluck N. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. Eur J Clin Microbiol Infect Dis 1998; 17:434-40.
65. 65. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27:730-8.
66. 66. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27:722-9.
67. 67. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27:764-70.
68. 68. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26:811-38.
69. 69. Örtqvist Å, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia - a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110:1499-506.
70. 70. Portier H, May T, Proust A, et al. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37:83-91.
71. 71. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB. Sparfloxacin European Study Group. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26:1312-20.
72. 72. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40:73-81.
73. 73. Trémolières F, De Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 447-53.
74. 74. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-72.
75. 75. Edelstein PH. Antimicrobial chemotherapy for Legionnaire's disease: time for a change. Ann Intern Med 1998; 129:328-30.
76. 76. Adelglass J, DeAbate CA, McElvaine P, Fowler CL, LoCocco J, Campbell T. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg 1999; 120:320-7.
77. 77. Gehanno P, Berche P. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. Sinusitis Study Group. J Antimicrob Chemother 1996; 37(Suppl A):105-14.
78. 78. Henry DC, Moller DJ Jr, Adelglass J, et al. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Clin Therapeutics 1999; 21:340-52.
79. 79. Sydnor TA, Kopp EJ, Anthony KE, LoCoco JM, Kim SS, Fowler CL. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann Allergy Asthma Immunol 1998; 80:357-62.
80. 80. Kern WV, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341:312-8.
81. 81. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305-11.
82. 82. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71:3640-6.
83. 83. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995; 98:224-31.
84. 84. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever - a prospective, randomized clinical trial. Cancer 1999; 85:213-9.
85. 85. Finberg RW, Talcott JA. Fever and neutropenia: how to use a new treatment strategy. N Engl J Med 1999; 341:362-3.
86. 86. Hooper DC. Mechanisms of quinolone resistance. Drug Resistance Updates 1999; 2:38-55.
87. 87. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351:797-9.
88. 88. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163:1279-85.
89. 89. Schmitz FJ, Jones ME, Hofmann B, et al. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother 1998; 42:1249-52.
90. 90. Pegues DA, Colby C, Hibberd PL, et al. The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphylococcal isolates: analysis of risk factors and strain types. Clin Infect Dis 1998; 26:72-9.
91. 91. Høiby N, Jarlov JO, Kemp M, et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349:167-9.
92. 92. Udo EE, Al-Obaid IA, Jacob LE, Chugh TD. Molecular characterization of epidemic ciprofloxacin-and methicillin-resistant Staphylococcus aureus strains colonizing patients in an intensive care unit. J Clin Microbiol 1996; 34:3242-4.
93. 93. Coronado VG, Edwards JR, Culver DH, Gaynes RP. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16: 71-5.
94. 94. Tanaka M, Matsumoto T, Kobayashi I, Uchino U, Kumazawa J. Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Japan. Antimicrob Agents Chemother 1995; 39:2367-70.
95. 95. Gordon SM, Carlyn CJ, Doyle LJ, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors. Ann Intern Med 1996; 125:465-70.
96. 96. Kilmarx PH, Knapp JS, Xia MS, et al. Intercity spread of gonococci with decreased susceptibility to fluoroquinolones: a unique focus in the United States. J Infect Dis 1998; 177:677-82.
97. 97. Endtz HP, Ruijs GJ, van Klingeren B, Jansen WH, van der Reyden T, Mouton RP. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27:199-208.
98. 98. Endtz HP, Mouton RP, van der Reyden T, Ruijs GJ, Biever M, van Klingeren B. Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products [letter] [see comments]. Lancet 1990; 335:787-8.
99. 99. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999; 340:1525-32.
100. 100. Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990; 150:541-6.
101. 101. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995; 153:117-20.
102. 102. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20:557-60.
103. 103. Oethinger M, Conrad S, Kaifel K, et al. Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother 1996; 40:387-92.
104. 104. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995; 39:520-4.
105. 105. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40:503-5.
106. 106. Rodriguez-Carballeira M, Garau J, Xercavins M, Gomez-Vera JR, Collroldua I. Emergence and dissemination of ciprofloxacin-resistant E. coli in the community [abstract C-18]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997: 49.
107. 107. Blanco JE, Blanco M, Mora A, Blanco J. Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherichia coli strains isolated from septicemic and healthy chickens in Spain. J Clin Microbiol 1997; 35:2184-5.
108. 108. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43:1310-3.
109. 109. Chen DK, McGeer A, de Azavedo JC, Low DE, the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-9.